The clinical trials of the two vaccine candidates developed in the Center for Genetic Engineering and Biotechnology (CIGB) of Cuba concluded the short cycle of its phase I.

Cuba studied 11,387 samples for COVID-19, with 292 positive tests. The country accumulates 1 ,701, 134 samples made and 18, 443 positive ones (1.8%).

The vaccine candidate Soberana 02, developed by the Finlay Institute of Vaccines, started today the second stage of phase two of the clinical trials in the municipality of Plaza de la Revolución in Havana.

Cuban minister of public health, Jose Angel Portal Miranda, said today that during the SARS-CoV-2 pandemic, Cuban scientists have taken great challenges to demonstrate their commitment to the health of the people, as well as the human and professional quality, modesty and selflessness that distinguish them.

Cuba studied 14, 550 samples for COVID 19, detecting 547 new cases. The conuntry has studied a total of 1, 663, 559 samples, with 17, 096 positive (1.02%).

The use of therapeutic drugs as part of the sanitary protocols of the Ministry of Public Health (MINSAP by its Spanish acronym) makes possible, to a great extent, the high rates of COVID-19 recoveries in Cuba, in spite of the current complex epidemiological situation.

A multidisciplinary team of specialists belonging to the Cuban Neuroscience Center (CNEURO) is developing pulmonary ventilators in the country, so that patients who need them can have access to this means of medical assistance.

Cuba studied 14, 579 samples of COVID 19, detecting 505 new cases. There are accumulated 1, 649, 009 samples carried out and 16, 549 positive (1.00%).

The Center for Genetic Engineering and Biotechnology (CIGB) is developing new vaccine candidates more resistant to possible SARS-CoV-2 mutations, which cause COVID-19, announced in this capital the Doctor in Biological Sciences Gerardo Guillén Nieto, Director of Biomedical Research at that institution.

Cuba studied 14, 261 samples which confirmed 550 new cases, the highest number of positive cases in one day. There are accumulated 1, 634, 430 samples carried out and 16, 044 positive ones (0.98%).

Cuba studied 14,350 samples to detect the COVID, detecting 487 new cases, for a total of 1,620,169 tests carried out and 15,494 positive ones (0.96%).

At the closing of January 10, Cuba studied 13,212 samples to detect COVID 19, accumulating 1,605,819 tests carried out, and 431 new positive cases, 44 of which were patients of pediatric age, under 20 years old.

 The Finlay Institute of Vaccines, belonging to the Group of Biotechnological and Pharmaceutical Industries of Cuba, BioCubaFarma, signed a bilateral agreement with Iran to complement clinical evidence of the Soberana 02 vaccine candidate.

Cuba studied 12,092 samples, resulting in 344 new positive ones to SARS-CoV-2 coronavirus, accumulating already 1,565,666 of tests carried out and 13,823 confirmed cases since March.